Decision: Favourable

Decisions Table

Study Title:

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

  • NREC Code:

    21-NREC-CT-014

  • Decision:

    Favourable

  • Meeting Date:

    07/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Ray McDermott

  • PI Institution:

    Tallaght University Hospital

  • Sponsor:

    Covance CAPS Ltd Authorised by Merck Sharp & Dohme Corp

Scroll to Top